New caregiver resource focuses on quality of life in later stages of dementia
Much of the progress in Alzheimer's disease research in recent years has focused on preventing or slowing the disease in its earliest stages. But for millions of people already living with advanced dementia—and the families caring for them—another question remains: How can we make life better now?
New caregiver guidance focusing on quality of life in advanced dementia stages has emerged from the University of Kentucky's Sanders-Brown Center on Aging. While much Alzheimer's research has targeted early prevention, this new resource addresses the challenges faced by millions living with advanced dementia and their families. Researchers emphasize the importance of preserving comfort, dignity, and quality of life in the later stages of the disease, as traditional options are limited.
The LiBBY clinical trial, conducted in Kentucky, aimed to explore a potential new approach for managing agitation in late-stage dementia. Agitation, characterized by restlessness, pacing, repetitive movements, or verbal/aggressive behavior, can signal distress and significantly impact quality of life and caregiver burden. Existing medications for agitation carry risks, particularly for older and medically vulnerable individuals.
The 12-week randomized, double-blind study included 120 participants and demonstrated that cannabis-derived THC/CBD treatment led to substantial reductions in agitation compared to placebo. Participants receiving treatment showed an 87.2% overall improvement at week 12, while only 23.6% of placebo recipients improved. Importantly, side effects were similar between groups, with none being serious or related to the medication.
The research team, including director of clinical trials Greg Jicha, noted that the reduction in agitation did not involve sedation, allowing participants to remain awake, alert, and comfortable. Furthermore, improvements in caregiver quality of life were observed, highlighting the importance of addressing agitation without simply sedating patients.
While the findings should not be generalized to all cannabis or THC/CBD products, they offer a promising foundation for further research. The trial also demonstrated the feasibility of including individuals with advanced dementia in clinical trials, even those with significant physical limitations. This approach prioritizes the needs of both patients and their caregivers, ensuring that future dementia research considers the unique challenges faced by those in late-stage disease.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
